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Abstract
Background: Regular physical activity is recommended for all people with chronic obstructive pulmonary disease
(COPD), but the dose of physical activity required to gain mortality benefit in this population is not yet known. This
aim of this study was to examine the associations of total and type-specific physical activity with mortality risk in
people with COPD.
Methods: People with COPD aged ≥40 years were identified from the 1997 Health Survey for England and the
1998 and 2003 Scottish Health Survey cohorts. Self-reported total physical activity, moderate-vigorous intensity
physical activity (MVPA), walking, domestic physical activity, and sport/exercise were assessed at baseline. Cox
proportional hazards models were used to examine the associations between physical activity and mortality risk.
Results: Two thousand three hundred ninety-eight participants with COPD were included in the analysis and
followed up for a mean 8.5 (SD 3.9) years. For both total physical activity and MVPA, we observed dose-
response associations with all-cause and cardiovascular disease (CVD) mortality risk, and with respiratory
mortality risk to a lesser extent. Compared to those who reported no physical activity, participants who met
the physical activity guidelines demonstrated the greatest reductions in all-cause (HR 0.56, 95% CI 0.45–0.69),
CVD (HR 0.48, 95% CI 0.32–0.71) and respiratory mortality risk (HR 0.40, 95% CI 0.24–0.67). Participants who
reported a level of physical activity of at least half the dosage recommended by the guidelines also had a
reduced risk of all-cause (HR 0.75, 95% CI 0.56–1.00) and CVD mortality (HR 0.48, 95% CI 0.26–0.88). Dose-
response associations with mortality risk were demonstrated for walking and sport/exercise, but not domestic
physical activity.
Conclusions: We found a dose-response association between physical activity and all-cause and CVD
mortality risk in people with COPD, with protective effects appearing at levels considerably lower than the
general physical activity recommendations. People with COPD may benefit from engagement in low levels of
physical activity, particularly walking and structured exercise.
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Background
Compared to their healthy peers, people with chronic
obstructive pulmonary disease (COPD) engage in a
lower intensity of daily physical activity (PA), and spend
significantly more time sitting and lying down [1, 2].
This has been attributed to disease-specific limitations
such as dyspnoea, fatigue and reduced exercise toler-
ance, which reduce the capacity of people with COPD to
engage in moderate-vigorous intensity physical activity
(MVPA) [3]. Previous cohort studies have consistently
shown that low levels of PA are associated with an in-
creased risk of all-cause and respiratory mortality in
people with COPD, as well as an increased risk of COPD
exacerbations, irrespective of the degree of airflow ob-
struction [4]. Low levels of PA are also associated with
an increased risk of hospitalisation, re-hospitalisation
after an acute exacerbation, and longer hospital length
of stay [4, 5].
Although regular PA is recommended for all patients
with COPD [6], there is a lack of high-quality evidence on
which to base specific PA recommendations for this popu-
lation, in particular the dose of PA required to gain mor-
tality benefit. A Spanish cohort study of 611 people with
COPD found that those who “took walks regularly for
>8 km, no less than 5 days a week, or practised
sports” had a lower mortality risk compared to those
who “don’t leave the house and life is limited to the
bed or armchair, or to doing some domestic chores”
(risk ratio (RR) 0.38, 95% confidence interval (CI)
0.11–1.29) [7]. Another cohort study of 173 people
with moderate to very severe COPD, which used
accelerometry to measure PA levels, found that every
ten vector-magnitude unit (VMU) increase in daily
PA was associated with a 14% reduction in mortality
risk [8]. Such studies are limited by the use of small
non-representative samples of people with COPD to
examine the association between PA and mortality
risk, and by arbitrary definitions of what constitutes
“low” and “high” levels of PA. Many different ques-
tionnaires and activity monitors have been used to
assess PA in people with COPD, and the optimal
mode of reporting (e.g., energy expenditure, number
of steps/day) is not yet known [4, 9].
The considerable heterogeneity in the way that PA
has been classified and reported in previous studies
has made it difficult to develop PA guidelines specific
to people with COPD, and subsequently clinicians
must rely on the PA guidelines for the general popu-
lation to inform clinical recommendations [10]. It is
unknown whether specific types of PA, such as walk-
ing and domestic PA, are associated with reductions
in mortality risk. Exploring types of PA that are rele-
vant to functionally limited populations such COPD,
and the dose of PA required to gain mortality benefit,
is necessary in order to guide the prescription of PA
in clinical practice and to inform interventions which
aim to increase PA.
The aim of this study was to examine the associations
between total and type-specific PA and mortality risk in
a series of representative cohorts of adults with COPD,
specifically:
1. The dose-response association between total PA
and the risk of all-cause, cardiovascular disease
(CVD), and respiratory mortality within the
context of current public health recommendations;
and
2. The dose-response association between specific types
of PA and the risk of all-cause, CVD, and respiratory
mortality.
Methods
Study design
The Health Survey for England (HSE) and Scottish Health
Survey (SHS) cohorts are general population-based health
examinations of individuals aged ≥16 years living in house-
holds in England and Scotland respectively. Participants
were selected using a multistage stratified probability de-
sign, based on geographical location, to provide a nationally
representative sample of the population in each constituent
country. Further details on the HSE/SHS sampling methods
can be found elsewhere [11, 12].
Participants for the present analysis were drawn from
the HSE and SHS survey cohorts with available data on
lung function and PA (HSE 1997 and SHS 1998, 2003),
and were linked prospectively to National Health Service
mortality data. The surveys consisted of two household
visits: an interviewer visit, to collect information on phys-
ical and mental health and health behaviours, followed by
a nurse visit to obtain physiological measures. Response
rates for the interviewer visit ranged from 76 to 83%, and
31 to 44% for the subsequent nurse visit. Ethics approvals
for the HSE and SHS were obtained from the London
Research Ethics Council and Scotland Local Research Ethics
Councils respectively. Participants gave written informed
consent.
Participants
There were two eligibility criteria to identify participants
with COPD: (1) age ≥ 40 years, and (2) meeting the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
spirometric criteria for COPD (forced expiratory volume
in one second (FEV1)/forced vital capacity (FVC) ratio of
< 0.7) [3]. Participants were followed-up to the time of
death or, if there was no record of an event, data were
censored at February 15, 2011 (HSE) and at December 31,
2009 (SHS).
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Measurements
Participant characteristics
Interviewers used computer-assisted interviewing mod-
ules to collect information on participants’ demographic
and socioeconomic characteristics, self-reported health
status, and other health behaviours (e.g., smoking, alco-
hol consumption).
Lung function
Spirometry was performed using a Vitalograph® Escort
spirometer, which was calibrated prior to each partici-
pant’s use. Participants who normally required bron-
chodilator medication prior to strenuous exercise
were allowed to take their usual medication before
spirometry was performed. No additional bronchodila-
tors were given by the survey nurses. Participants
performed at least one practice attempt, followed by
five attempts or until they were deemed too tired to
continue. The best of the five attempts (excluding any
technically unsatisfactory attempts, e.g., coughing dur-
ing the blow, air leak around the mouthpiece) was
used as the final result. The full spirometry protocol
has been published elsewhere [13].
Physical activity
The Physical Activity and Sedentary Behaviour Assessment
Questionnaire (PASBAQ) was used to collect data on phys-
ical activity. Participants reported the frequency (number of
days in the last 4 weeks) and duration (of an average episode)
of participation in four domains of PA: (1) “light” (e.g. gen-
eral tidying) and “heavy” (e.g. spring cleaning) domestic activ-
ity; (2) “light” and “heavy” manual work, gardening and “do-
it-yourself” activities; (3) light-intensity (slow/average pace)
and moderate-intensity (fairly brisk/fast pace) walking; and
(4) sport/exercise. Intensity of sport/exercise was determined
by whether the activity had made participants “out of
breath or sweaty”, and by the nature of the activity as
indexed in the metabolic equivalent (MET) compen-
dium [14]. The PASBAQ has demonstrated satisfac-
tory validity when compared against accelerometry
data in a representative sample of British adults;
Spearman’s correlation coefficients were 0.20 (95%
confidence interval (CI) 0.25–0.35) in men and 0.30
(95% CI 0.15–0.26) in women [15]. Participation in
PA was then calculated in MET-hours/week by multi-
plying the volume of activity (frequency x duration)
by the intensity of the activity in METs [14].
Five PA variables were derived for the analyses: MET-
hours/week of total non-occupational PA, walking, domes-
tic PA, and sport/exercise, and minutes/week of MVPA.
Total PA and MVPA were converted into four categories
based on adherence to the general PA recommendations
(i.e., at least 150 min/week of moderate-intensity aerobic
PA (MPA), or at least 75 min/week of vigorous-intensity
aerobic PA (VPA), or an equivalent combination of MVPA)
[10]. This recommendation is equivalent to 7.5 MET-
hours/week of PA [16]. Participants were classified as
‘Inactive’ (0 MET-hours/week of total PA, 0 min/week of
MVPA), ‘Insufficiently Active (Low)’ (< 3.75 MET-hours/
week of total PA, < 75 min/week of MPA or equivalent
combination of MVPA), ‘Insufficiently Active (High)’ (3.75
to < 7.5 MET-hours/week of total PA, 75 to < 150 min/
week of MPA or equivalent combination of MVPA), or ‘Suf-
ficiently Active’ (≥7.5 MET-hours/week of PA, ≥150 min/
week of MPA or equivalent combination of MVPA). Partici-
pants who reported no PA were specified as the referent
group. This method of classifying PA has been used in other
cohort studies of people with COPD [5].
The walking, domestic PA, and sport/exercise vari-
ables were converted into three categories. The ref-
erent group was specified as no participation in
walking, domestic PA, or sport/exercise respectively
(‘No PA’). For each type of PA, the remaining partic-
ipants were divided into one of two groups: below
the median level of activity of the cohort (‘Low PA’),
or equal to or above the median level of activity of
the cohort (‘High PA’). The medians were 5.25 MET-
hours/week for walking, 5.70 MET-hours/week for
domestic PA, and 8.00 MET-hours/week for sport/
exercise. Previous studies have used this approach to
distribute participants evenly into each category and
ensure that the Cox proportional hazards assumption
is met [17].
Mortality
The study outcomes were all-cause mortality, CVD mor-
tality, and respiratory mortality. The primary cause of
death was identified from the death certificate and from
any additional information provided by the certifying
physician, and was recorded according to the Inter-
national Classification of Diseases (ICD) Ninth and
Tenth Revisions. CVD codes were 390 to 459 (ICD-9)
and I01 to I99 (ICD-10), and respiratory codes 460 to
519 (ICD-9) and J00 to J99 (ICD-10).
Covariates
Potential confounders were identified a priori from a re-
view of current literature [5, 16, 18] and the most parsi-
monious selection of variables that achieved the greatest
control of confounding was used. The following covari-
ates were included in the analyses: age, sex, ethnicity
(Caucasian, non-Caucasian), severity of COPD (mild,
moderate, severe, or very severe according to the GOLD
stages [3]), history of CVD at baseline, history of cancer
at baseline, history of diabetes at baseline, self-reported
longstanding illness, body mass index (BMI), smoking
status (current smoker, ex-smoker, never smoked), age
finished full-time education (< 14 years, 15–18 years,
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≥19 years), and alcohol consumption (does not drink,
less than once a week, 1–4 times/week, ≥5 times/week).
Statistical analyses
Differences in the distribution of baseline characteristics
were examined using chi-square tests for categorical var-
iables and analysis of variance (ANOVA) for continuous
variables. Cox proportional hazards regression models
were used to compute hazard ratios (HR) with 95% CIs
and compare mortality risk across the categories of PA.
The proportional hazards assumption was examined by
comparing the cumulative hazard plots of the five PA vari-
ables. No appreciable violations were noted. Covariates
were added to the model in three stages: age, sex and eth-
nicity (Model 1); plus severity of COPD, history of CVD,
history of cancer, history of diabetes, self-reported long-
standing illness, and BMI (Model 2); plus smoking status,
age finished full time education, and alcohol consumption
(Model 3). Analyses of walking, domestic PA and sport/
exercise were also mutually adjusted for the other types of
PA. Participants with missing data for mortality (n = 243)
or for any of the covariates (n = 490) were excluded from
the analyses.
Two sensitivity analyses were performed. To minimise
the potential for reverse causality in the main analysis
(i.e., that participants had an increased risk of mortality
because of pre-existing medical conditions rather than
their PA levels), the first excluded those who had died
within the first 12 months of follow-up (n = 49), and
those with existing CVD (n = 339), cancer (n = 135),
and diabetes (n = 123) at baseline. Additional sensitivity
analyses were conducted to exclude those who had died
within the first 2 years of follow-up (n = 124) and within
the first 3 years of follow-up (n = 196). As no appre-
ciable differences were found, these participants were
retained in the main analyses. To assess for misclassifi-
cation of a diagnosis of COPD, the second excluded
participants who had never smoked (n = 664), those
with a history of asthma (n = 243), and those who re-
ported a respiratory infection in the 3 weeks prior to the
first household visit (n = 353). All statistical tests were
two-sided, with a p-value < 0.05 considered statistically
significant. All analyses were performed using SPSS
Version 22.0 (IBM Corp, USA).
Results
Of the 19,000 participants with available data on lung
function and PA, 2398 participants met the eligibility
criteria for COPD and were included in the analysis. The
mean age of the sample was 62.6 (SD 11.5) years and
52% were men. There was a high prevalence of COPD of
mild (42.7%) and moderate (37.5%) severity, and of
never-smokers (27.9%). Baseline characteristics, grouped
according to the degree of adherence to the general PA
recommendations, are displayed in Table 1. Participants
who reported no PA were older, had COPD of greater
severity, had more medical comorbidities, and had a
lower level of education (p < 0.001). Mortality data were
available for 2155 participants. Over a mean 8.5 (3.9)
years follow-up, there were 571 deaths (26%) of which
172 were CVD-related deaths and 105 were respiratory-
related deaths, corresponding to a total of 18,222 person
years.
The associations of MET-hours/week of total PA and
minutes/week of MVPA with mortality risk are shown in
Table 2. Dose-response associations with all-cause, CVD
and respiratory mortality risk were demonstrated for
total PA and MVPA. Participants in the ‘Insufficiently
Active (High)’ group for total PA had a reduced risk of
all-cause and CVD mortality compared to those who
reported no PA, but no significant mortality risk reduc-
tions were observed in the ‘Insufficiently Active (Low)’
group for total PA (Fig. 1). Conversely, participants in
the ‘Insufficiently Active (Low)’ group for MVPA had a
reduced risk of all-cause mortality compared to those
who reported no MVPA (Fig. 2). These dose-response
associations were also observed in the sensitivity ana-
lyses (Additional file 1: Tables S1 and S2).
The associations of MET-hours/week of walking, do-
mestic PA, and sport/exercise with mortality risk are
shown in Table 3. Dose-response associations with all-
cause, CVD and respiratory mortality risk were demon-
strated for walking, with no significant mortality risk re-
ductions observed in the ‘low’ walking group. There
was a dose-response association between sport/exer-
cise and all-cause mortality risk, but not CVD or re-
spiratory mortality risk. The few number of CVD and
respiratory deaths in the ‘low’ and ‘high’ categories of
sport/exercise have likely contributed to this result.
Domestic PA of any level was not associated with re-
ductions in mortality risk. Similar results were dem-
onstrated in the sensitivity analyses (Additional file 1:
Tables S3 and S4).
Discussion
This study of 2398 participants who met the GOLD spi-
rometric criteria for COPD provides a detailed analysis
of the dose-response associations between PA and mor-
tality risk within the context of current public health
recommendations, and for specific types of PA. The use
of established thresholds to examine PA in both MET-
hours/week and minutes/week provides clinicians with a
meaningful reference standard to guide prescription of
PA, and enables future studies to make direct compari-
sons to the magnitude of mortality risk described in this
sample. This is the first population-based cohort study
of people with COPD to examine whether specific types
of PA confer mortality benefit, which has high clinical
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relevance when developing interventions to increase PA
in people with COPD.
Dose-response associations with mortality risk were dem-
onstrated for total PA, MVPA, walking and sport/exercise,
but not domestic PA. A previous Danish population-based
cohort study of people with COPD, which compared sub-
jects who reported low, moderate, or high levels of PA to
subjects who reported a very low level of PA, showed that
some level of regular PA was associated with a lower risk of
all-cause and respiratory mortality [18]. In our study,
reductions in mortality risk of the greatest magnitude were
observed in participants who adhered to the PA guidelines.
Compared to those who reported no PA, participants who
were ‘Sufficiently Active’ showed a 45% reduction in all-
cause mortality risk, a 50–55% reduction in CVD mortality
risk, and a 55–60% reduction in respiratory mortality risk.
Although there is added benefit in adhering to the PA
guidelines, meeting such recommendations is often diffi-
cult for people with symptomatic COPD. This study
showed that participants who did not meet the guidelines
Table 1 Baseline characteristics of 2398 participants with COPD recruited from the Healthy Survey of England (1997) and Scottish
Health Survey (1998, 2003)
Variable All participants
(n = 2398)
Inactived
(n = 489)
Insufficiently
Active
(Low)e
(n = 386)
Insufficiently
Active (High)f
(n = 225)
Sufficiently
Activeg
(n = 1268)
p-value
Mean age, years 62.6 (11.5) 67.9 (11.6) 63.8 (10.9) 62.5 (11.3) 60.1 (11.0) < 0.001
Men, % 52.1 54.6 47.9 47.1 53.5 0.06
Caucasian, % 98.9 98.8 98.7 99.2 99.0 0.92
FEV1% predicted
a, % < 0.001
GOLD I: ≥80% pred. 42.7 26.0 37.8 41.1 49.7
GOLD II: 50% ≥ FEV1% < 80% pred. 37.5 40.5 41.2 39.0 35.2
GOLD III: 30% ≥ FEV1% < 50% pred. 14.5 25.2 15.4 15.8 10.6
GOLD IV: FEV1 < 30% pred. 5.3 8.3 5.6 4.1 4.5
History of CVDb, % 14.1 28.4 18.7 11.8 7.7 < 0.001
History of cancer, % 5.6 6.1 6.0 5.1 5.4 0.91
History of diabetesc, % 5.1 10.0 7.3 4.7 2.7 < 0.001
Self-reported longstanding illness, % 62.2 85.5 69.2 61.2 51.3 < 0.001
Self-reported asthma, % 10.1 13.9 10.6 9.8 8.6 0.01
Mean BMI, kg/m2 26.6 (4.7) 27.3 (5.5) 27.1 (4.9) 26.6 (5.0) 26.3 (4.3) 0.001
Smoking status, % < 0.001
Current 37.2 42.7 38.6 38.6 34.4
Ex 34.9 37.1 33.2 36.2 34.3
Never 27.9 20.2 28.2 25.2 31.3
Aged finished full-time education, % < 0.001
≤ 14 years 28.7 45.7 32.6 27.1 21.2
15–18 years 59.4 48.2 57.8 61.2 63.8
19 years and older 12.0 6.1 9.6 11.8 15.0
Alcohol consumption, % < 0.001
Does not drink 13.1 22.5 13.5 11.4 9.6
Less than once per week 26.9 27.4 31.9 30.2 24.6
1–4 times/week 37.4 29.2 35.0 35.7 41.6
≥ 5 times/week 22.6 20.9 19.7 22.7 24.1
Values are means (SD) unless otherwise stated
FEV1 forced expiratory volume in 1 second, CVD cardiovascular disease, BMI body mass index
aCOPD severity was classified according to Global Initiative for Lung Disease (GOLD) stages
bA history of cardiovascular disease was defined as self-reported or doctor-diagnosed angina, heart attack or stroke
cA history of diabetes was defined as self-reported or doctor-diagnosed diabetes, and glycated haemoglobin (HBa1C) ≥6.5%
dParticipants who reported no physical activity during the week
eParticipants who reported < 3.75 MET-hours/week of physical activity
fParticipants who reported between 3.75 and < 7.5 MET-hours/week of physical activity
gParticipants who reported ≥7.5 MET-hours/week of physical activity as per current public health recommendations
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but reported at least 3.75 MET-hours/week of total
PA, or reported some level of MVPA, still had signifi-
cant reductions in mortality risk. After taking the
sensitivity analyses into consideration, which yielded
similar mortality risk reductions in participants with-
out existing CVD, cancer and diabetes, these results
suggest that the dose of PA required to gain mortality
benefit in COPD may be lower than is currently esti-
mated. This is consistent with previous observations
that relatively low levels of PA have beneficial effects
on mortality risk in people with COPD. It has been
suggested that as little as 2 h/week of walking or cyc-
ling is associated with a 30–40% risk reduction in re-
spiratory mortality and COPD hospitalisation [18].
In both the main and sensitivity analyses, participants
in the ‘Insufficiently Active (Low)’ group for MVPA had
a significant reduction in all-cause mortality risk (HR 0.75,
95% CI 0.61–0.94). However, no significant reductions in
all-cause mortality risk were observed in participants who
reported < 3.75 MET-hours/week of total PA (HR 0.86,
95% CI 0.67–1.10). This subtle difference between the two
equivalent measures of PA is likely due to error in the
calculation of MET-hours/week of total PA, in which the
intensity of PA is approximated according to the nature of
the activity as indexed in the MET compendium. Whether
higher intensity PA has beneficial effects on mortality risk
independent of the volume of activity is not yet known in
people with COPD. A Spanish cohort study demonstrated
a 20% reduction in the risk of COPD hospitalisation for
every additional 1000 daily steps at low average intensity,
but no change in hospitalisation risk with additional steps
at high average intensity [19]. Conversely, higher intensity
PA was associated with a lower prevalence of metabolic
syndrome in 223 subjects with COPD drawn from the
National Health and Nutrition Examination Survey 2003–
2006 dataset [20]. Considering the innate challenges of
Fig. 1 The association of total physical activity with all-cause mortality risk in participants with COPD (n = 2155). The figure shows the dose-response
association of total physical activity (PA) with all-cause mortality risk based on adherence to the general PA recommendations. Participants were
classified as ‘Inactive’ (0 MET-hours/week of total PA), ‘Insufficiently Active (Low)’ (< 3.75 MET-hours/week of total PA), ‘Insufficiently Active (High)’ (3.75
to < 7.5 MET-hours/week of total PA), or ‘Sufficiently Active’ (≥7.5 MET-hours/week of PA)
Fig. 2 The association of moderate-vigorous intensity physical activity with all-cause mortality risk in participants with COPD (n = 2155). The figure
shows the dose-response association of moderate-vigorous physical activity (MVPA) with all-cause mortality risk based on adherence to the
general physical activity (PA) recommendations. Participants were classified as ‘Inactive’ (0 min/week of MVPA), ‘Insufficiently Active (Low)’
(< 75 min/week of moderate-intensity PA or equivalent combination of MVPA), ‘Insufficiently Active (High)’ (75 to < 150 min/week of moderate-
intensity PA or equivalent combination of MVPA), or ‘Sufficiently Active’ (≥150 min/week of moderate-intensity PA or equivalent combination
of MVPA)
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increasing MVPA in people with COPD, encouraging
more light-intensity PA in this population may be a first
and more realistic step than targeting MVPA alone.
Although there was a dose-response association
between sport/exercise and mortality risk, sport is
not feasible for most people with COPD due to the
older age of the population and the high prevalence
of comorbidities such as poly-pharmacy and mobility
problems [21], which are associated with poorer
physical performance [22]. Walking, however, is an
achievable and accessible type of PA. It requires no
specialised exercise equipment and, in the form of ground
walking or treadmill walking, is commonly undertaken as
part of pulmonary rehabilitation programs with good
effect [23]. This study showed that participants who re-
ported at least 5.25 MET-hours/week of walking (approxi-
mately equivalent to 105 min/week of brisk walking) had
a 30% reduction in all-cause mortality risk, a 44% reduc-
tion in CVD mortality risk, and a 53% reduction in re-
spiratory mortality risk compared to those who reported
no walking. Future studies should explore strategies for in-
corporating more walking into daily life for people with
COPD. Nordic walking is one such strategy, where im-
provements in PA were maintained to 3 months in the
group of participants [24].
Although domestic PA is feasible for most people with
COPD, this study showed no association between
domestic PA of any level and mortality risk. There is
conflicting evidence about the protective effect of do-
mestic PA on mortality. The domain is often poorly de-
fined; for example, housework and gardening are both
treated as domestic PA despite most housework activ-
ities being classified as light intensity, since they do not
require locomotion or the use of large muscles groups
[25]. An English population-based study of 15,000 adults
found that PA “around the home”, such as lawn mowing
and digging, was inversely related to all-cause mortality
risk [26]. However, a recent study of the SHS cohort
found no association between intense domestic PA and
CVD mortality risk after adjusting for relevant con-
founders [17]. The inclusion of more light intensity
activities in our definition of domestic PA may explain
the absence of a dose-response association between do-
mestic PA and mortality risk.
Our study has several limitations. A fixed FEV1/FVC ra-
tio was used to identify participants with COPD due to a
lack of other information that may have helped to confirm
a diagnosis. Although COPD can be identified with high
diagnostic accuracy using spirometry, a fixed ratio of
obstruction would not take into account any reversible
factors that may have influenced FEV1, such as asthma or
a respiratory infection on the day of testing. Spirometry
performed on 219 adults in a general practice setting
showed a sensitivity of 0.92 (95% CI 0.80–0.97) for
diagnosing COPD, with eight “false positives” identified
from further laboratory testing [27]. To account for mis-
classification of COPD in our study, we conducted sensi-
tivity analyses which excluded participants with asthma
and/or a recent respiratory infection, and these yielded
similar results to the main analysis.
Misclassification of the PA variables is also possible, since
self-reported methods were used to quantify PA and any
changes in PA levels during follow-up were not accounted
for. This would have most likely reduced the magnitude of
the effect of PA on mortality risk [28]. It is well-established
that self-report PA questionnaires tend to overestimate the
time spent physically active [29] as they are reliant on
respondent recall and are often subject to social desirability
bias [30], and thus should be interpreted with caution.
Nevertheless, self-report questionnaires are frequently
used to estimate PA levels in national populations for rea-
sons of feasibility, cost-effectiveness, and to obtain infor-
mation on specific types and domains of PA, which are
not captured by objective measures. In comparison with
accelerometry, the PASBAQ has demonstrated criterion
validity similar to that of other questionnaires used in
national surveys [15]. While there is no universally accept-
able level for the magnitude of criterion validity coefficients
for self-report PA questionnaires versus accelerometry,
multiple reviews have indicated that correlations rarely ex-
ceed 0.40 [31–33].
Smoking history was not used as an eligibility criterion
to identify participants with COPD due to a lack of
available data to quantify smoking history in pack-years,
and to preserve sample size. While the high prevalence
of never-smokers in our sample (27.9%) is surprising, it
is supported by a recent case-finding study of 74,818 pa-
tients with COPD showing that 20–26% of patients were
never-smokers [34]. Exposure to second-hand smoke,
pollutants, and occupational exposure to dusts and chemi-
cals are other risk factors for COPD [3], and may explain
the high proportion of never-smokers in the sample.
Furthermore, sensitivity analyses excluding never-smokers
yielded similar results to the main analysis. It is therefore
unlikely that the inclusion of never-smokers in the analysis
would have biased the magnitude of the effect of PA on
mortality risk.
Finally, given that the HSE and SHS are general
population-based health examinations and are not specific-
ally designed to investigate people with COPD, some po-
tential confounders may not have been captured and this
may limit the generalisability of the results. These include
history of previous exacerbations, COPD hospitalisations,
exercise capacity at baseline, and severity of symptoms,
which are known predictors of mortality [35–37]. The high
proportion of mild and moderate COPD in the sample may
also limit the generalisability of the results to people with
COPD of greater severity.
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Conclusions
We observed a linear dose-response association between
PA and all-cause, CVD and respiratory mortality risk in
people with COPD. There is added mortality benefit in
adhering to the PA guidelines, although engaging in PA
above a threshold of 3.75 MET-hours/week (at least
75 min/week of MPA, 32.5 min of VPA, or an equivalent
combination of MVPA) is still associated with significant
reductions in mortality risk. Walking and structured ex-
ercise should be encouraged in people with COPD, but
the effects of domestic PA on mortality remain unclear.
Our results reinforce the importance of promoting regu-
lar PA as part of routine management of COPD, and the
need for effective strategies to increase PA in this
population.
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